We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sekisui XenoTech Announces Creation of Scientific Advisory Board (SAB)
Product News

Sekisui XenoTech Announces Creation of Scientific Advisory Board (SAB)

Sekisui XenoTech Announces Creation of Scientific Advisory Board (SAB)
Product News

Sekisui XenoTech Announces Creation of Scientific Advisory Board (SAB)

Dr. Brian Ogilvie, Vice President of Scientific Consulting for Sekisui XenoTech

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Sekisui XenoTech Announces Creation of Scientific Advisory Board (SAB)"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sekisui XenoTech has created a Scientific Advisory Board (SAB) of renowned scientists and thought leaders in the pharmaceutical industry.

Initially this board will be made up of four experts specializing in Absorption, Distribution, Metabolism and Excretion (ADME) studies, as well as Drug Metabolism and Pharmacokinetics (DMPK). The board will be led by Dr. Brian Ogilvie, Vice President of Scientific Consulting for Sekisui XenoTech.

Dr. Ogilvie sought out thought leaders that have distinctive perspectives on the pharmaceutical industry that have been formulated from their independent expertise and numerous years of experience. Through their insight Sekisui XenoTech will be guided to better serve the industry by anticipating growth trends, scientific innovation and ultimately the greater needs of its customers.

The SAB consists of: Dr. Griff Humphreys, Principal with Aranmore Pharma Consulting; Dr. Jane Kenny, Associate Director/Principal Scientist at Genentech; Dr. Ajay Madan, Vice President, Development for Crinetics Pharmaceuticals; and Dr. Larry Wienkers, Owner of Wienkers Consulting, LLC. For more information on the SAB members, please consult Sekisui XenoTech’s website.

“I am excited to bring this group together. The combination of our internal knowledge and 25 years of experience in the industry with the infusion of the extensive expertise and well-respected knowledge brought by this SAB will serve to set Sekisui XenoTech apart as the leader in in vitro ADME/DMPK/DDI testing services and products.” stated Dr. Ogilvie.
Advertisement